Why Compugen Stock Got Slammed Today
Compugen (NASDAQ: CGEN) stock didn't begin this week in a healthy way. The clinical-stage drug company's shares fell by just over 7% following a price target cut from an analyst tracking the company.
Prognosticator Mark Breidenbach of Oppenheimer has trimmed said target by just over 10% to $17 per share from the previous $19. Yet he is maintaining his outperform -- i.e., buy -- rating on the shares.
Source Fool.com